Market Trends Neutral 5

Relmada and NeurAxis Q4 Results Signal Pivotal 2026 for CNS Innovation

Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies. Both companies are positioning themselves as leaders in non-traditional treatments for depression and pediatric pain, respectively.

· 3 min read · Verified by 3 sources · By Healthcare Intelligence Brief

Beat this week

Last 7 days · Market Trends

2 stories
6 avg impact
50% positive
0% negative
vs prior 7 days -1 -1 story vs prior 7 days

Impact 6.0/10 (+0.3 vs prior). Counts are stories in our record, not a market forecast.

Open the change report

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.

  • 50% positive
  • 50% neutral

This story sits in Market Trends — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.

Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.

Share

Healthcare briefing

Key takeaways

5 impact
Neutralsentiment
3sources
3min read
  1. Relmada Therapeutics and NeurAxis reported Q4 2025 results, highlighting a strategic shift toward late-stage clinical readouts and expanded commercial coverage for CNS therapies.
  2. Both companies are positioning themselves as leaders in non-traditional treatments for depression and pediatric pain, respectively.
Drawn from
  • seekingalpha.com
  • insidermonkey.com

In this briefing

Mentioned

Key Intelligence

Key Facts

  1. 1Relmada is advancing REL-1017 through the Phase 3 Reliance II study for Major Depressive Disorder.
  2. 2NeurAxis reported expanded commercial insurance coverage for its IB-Stim pediatric neuromodulation device.
  3. 3Relmada has implemented stricter patient screening to reduce placebo response in clinical trials.
  4. 4NeurAxis is targeting functional abdominal pain in children, a market with few non-drug options.
  5. 5Both companies confirmed cash runways sufficient to reach major 2026 clinical and regulatory milestones.
CNS Innovation Outlook

Analysis

The fourth-quarter 2025 earnings reports from Relmada Therapeutics and NeurAxis underscore a significant transition in the central nervous system (CNS) therapeutic landscape. As the industry moves away from traditional SSRIs and opioid-based pain management, these two companies represent the dual-track progress of pharmacological innovation and neuromodulation technology. For Relmada, the focus remains squarely on the successful execution of its Phase 3 program for REL-1017, while NeurAxis is navigating the complex waters of medical device reimbursement and market penetration for its IB-Stim platform.

Relmada Therapeutics is currently at a critical juncture with its lead candidate, REL-1017 (esmethadone), an NMDA receptor antagonist designed for the adjunctive treatment of Major Depressive Disorder (MDD). Following previous setbacks in the Reliance III trial, the company has refined its clinical strategy, focusing on the ongoing Reliance II and Reliance-OLS (long-term safety) studies. CEO Sergio Traversa emphasized during the call that the company has implemented more rigorous screening processes to mitigate the high placebo response rates that have historically plagued depression trials. This strategic pivot is essential for Relmada, as the MDD market is increasingly crowded with rapid-acting antidepressants like Spravato and Auvelity. The company’s ability to demonstrate a superior safety profile and sustained efficacy will be the primary driver of its valuation heading into 2026.

For Relmada, the focus remains squarely on the successful execution of its Phase 3 program for REL-1017, while NeurAxis is navigating the complex waters of medical device reimbursement and market penetration for its IB-Stim platform.

Financially, Relmada appears to have managed its burn rate effectively, providing a cash runway that extends through key clinical milestones. This is a vital metric for biotech investors who have become increasingly risk-averse in the current high-interest-rate environment. The company’s focus on esmethadone—a molecule that lacks the dissociative side effects of ketamine—positions it as a potentially more accessible option for community-based psychiatric care. If the Reliance II data, expected in the coming year, meets its primary endpoints, Relmada could transition from a clinical-stage R&D firm to a commercial-stage powerhouse in the multi-billion dollar depression market.

What to Watch

Simultaneously, NeurAxis is demonstrating the growing viability of neuromodulation in the pediatric space. Its IB-Stim device, which uses percutaneous electrical nerve field stimulation (PENFS) to treat functional abdominal pain associated with irritable bowel syndrome (IBS), represents a shift toward non-pharmacological interventions. The Q4 2025 call highlighted the company's progress in securing commercial insurance coverage, a traditional bottleneck for medical device startups. By moving from a 'cash-pay' or 'exception-only' model to broad-based coverage, NeurAxis is lowering the barrier to entry for pediatric gastroenterologists who are often hesitant to prescribe devices without clear reimbursement pathways.

The broader implication for the Health IT and MedTech sectors is the increasing integration of digital health and device data into the clinical workflow. NeurAxis’s success depends not just on the efficacy of IB-Stim, but on the ability of providers to track patient outcomes and justify the cost-benefit ratio to payers. This mirrors a trend across the CNS sector where 'precision psychiatry'—using data to match the right patient with the right treatment—is becoming the gold standard. As both Relmada and NeurAxis move toward their next phases of growth, the market will be watching for consistency in clinical data and the ability to scale operations in an increasingly competitive neurological healthcare environment. The coming year will likely define whether these novel approaches can achieve the commercial scale necessary to disrupt established treatment paradigms.

Source cluster

Primary reporting

3articles

Cite This Page

"Relmada and NeurAxis Q4 Results Signal Pivotal 2026 for CNS Innovation." Healthcare Intelligence Brief, March 20, 2026. https://gethealthbrief.com/story/relmada-neuraxis-q4-2025-earnings-cns-trends

Related Stories

Market Trends

Semaglutide tied to 40% fewer asthma attacks, 20% fewer COPD flare-ups

A real-world UK EHR study presented at ERS found semaglutide associated with 40% fewer asthma attacks and 20% fewer COPD flare-ups. Health systems should treat this as an early signal that GLP-1s may have respiratory benefits, not yet a treatment recommendation.

Market Trends

India Health Expo 2026 Moves From Generics to Biosimilars and AI

India's top commerce officials used the Bharat Health Global Expo 2026 to signal a policy pivot from affordable generics toward biosimilars and AI-enabled innovation. For healthcare leaders, the remarks point to evolving supply dynamics, potential new treatment options, and a stronger Indian role in global health resilience.

Market Trends

UCSF Maps 1,000+ Protein Interactions Linked to Profound Autism

A UCSF team mapped more than 1,000 protein interactions tied to autism risk genes, creating a molecular atlas that could guide future drug development and precision diagnostics. The study, published in Science, moves autism research from single-gene findings toward systems-level biology, with implications for biomarker discovery and patient stratification.

Market Trends

Casgevy's $2.2M Gene Therapy Expands to Ages 2+, Shifting Care

FDA expansion of Casgevy to children as young as two could enable earlier SCD/TDT intervention before irreversible organ damage. Health systems must now address cell therapy logistics, payer coverage, and the $2.2M cost.

How we covered this story

Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.

Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.

Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.

Signal on this pageWhat it tells you
Verified by N sourcesIndependent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly.
Impact score (1-10)Regulatory + financial + operational weight. 8+ signals an experienced-operator action item.
SentimentFive-tier classification trained on labeled healthcare-specific corpora.
TimelineWhere applicable, the related-events sequence that contextualizes today's development.